J Lung Cancer.  2003 Mar;2(1):6-9.

Adjuvant Chemotherapy for Completely Resected Non-Small Cell Lung Cancer

Affiliations
  • 1Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. swkim@amc.seoul.kr

Abstract

Lung cancer is the number one cause of cancer-related deaths in Korea. Nonsmall cell lung cancers account for about 80% of these cases. Because the long term survival of patients after a complete resection is poor, postoperative adjuvant chemotherapy seems to be a very promising concept. However, studies on postoperative chemotherapy, to date, have been disappointing. Recently, the International Adjuvant Lung Cancer Trial (IALT) reported an absolute 5% statistically significant 5-year survival benefit (p<0.03). Further studies, which could select patients favored with adjuvant chemotherapy, are necessary.

Keyword

Non-small cell lung cancer; Adjuvant chemotherapy

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Chemotherapy, Adjuvant*
Drug Therapy
Humans
Korea
Lung Neoplasms
Full Text Links
  • JLC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error